Literature DB >> 4157339

Biliary tract excretion of cefazolin, cephalothin, and cephaloridine in the presence of biliary tract disease.

K R Ratzan, C Ruiz, G L Irvin.   

Abstract

The biliary tract excretion of three cephalosporins, cefazolin, cephaloridine, and cephalothin, was compared in patients with biliary tract disease. In the absence of obstruction, mean antibiotic levels in bile from gall bladder and common duct in patients undergoing cholecystectomy were highest for cefazolin (17 and 31 mug/ml, respectively) than either cephaloridine (7 and 9 mug/ml) or cephalothin (1 and 4 mug/ml). Biliary tract levels generally paralleled serum levels. In no patient with cystic duct obstruction were any of the cephalosporins detectable in appreciable amounts in gall bladder bile. In patients with T-tube drainage given each of the three different cephalosporins on separate days, concentrations of cefazolin in bile were many-fold higher than either cephaloridine or cephalothin. Peak levels of cefazolin in T-tube bile averaged 51 mug/ml after intravenous and 26 mug/ml after intramuscular administration, whereas mean peak levels of cephalothin and cephaloridine were only 6 and 16 mug/ml, respectively. Here, too, T-tube levels reflected serum concentrations and obstruction to biliary flow impaired excretion of each of the drugs.

Entities:  

Mesh:

Substances:

Year:  1974        PMID: 4157339      PMCID: PMC444665          DOI: 10.1128/AAC.6.4.426

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  10 in total

1.  AMPICILLIN LEVELS IN HUMAN BILE.

Authors:  G A AYLIFFE; A DAVIES
Journal:  Br J Pharmacol Chemother       Date:  1965-02

2.  Cephalothin levels in human bile.

Authors:  M D Ram; S Watanatittan
Journal:  Arch Surg       Date:  1974-02

3.  The biliary excretion of cephalothin.

Authors:  J M Brogard; P Haegele; J J Kohler; M Dorner; J Lavillaureix; J Stahl
Journal:  Chemotherapy       Date:  1973       Impact factor: 2.544

4.  Gentamicin levels in the human biliary tract.

Authors:  H A Pitt; R B Roberts; W D Johnson
Journal:  J Infect Dis       Date:  1973-03       Impact factor: 5.226

5.  Bacteriologic studies of biliary tract infection.

Authors:  R J Flemma; L M Flint; S Osterhout; W W Shingleton
Journal:  Ann Surg       Date:  1967-10       Impact factor: 12.969

6.  Gentamicin and ampicillin in human bile.

Authors:  T Smithivas; P J Hyams; J J Rahal
Journal:  J Infect Dis       Date:  1971-12       Impact factor: 5.226

7.  Biliary excretion of antibiotics in man.

Authors:  G Acocella; R Mattiussi; F B Nicolis; R Pallanza; L T Tenconi
Journal:  Gut       Date:  1968-10       Impact factor: 23.059

8.  Ampicillin levels in human bile in the presence of biliary tract disease.

Authors:  P R Mortimer; D B Mackie; S Haynes
Journal:  Br Med J       Date:  1969-07-12

9.  Biliary excretion of a new semisynthetic cephalosporin, cephacetrile.

Authors:  J M Brogard; P Haegele; M Dorner; J Lavillaureix
Journal:  Antimicrob Agents Chemother       Date:  1973-01       Impact factor: 5.191

10.  Pharmacology of gentamicin in the biliary tract of humans.

Authors:  J Mendelson; J Portnoy; H Sigman
Journal:  Antimicrob Agents Chemother       Date:  1973-11       Impact factor: 5.191

  10 in total
  13 in total

1.  Comparison of ceftazidime concentrations in bile and serum.

Authors:  E Bouza; T Hellín; M Rodríguez-Creixems; J Martínez-Beltrán; E Loza; F Baquero
Journal:  Antimicrob Agents Chemother       Date:  1983-07       Impact factor: 5.191

2.  Biliary excretion of moxalactam.

Authors:  O V Martinez; J U Levi; A Livingstone; T I Malinin; R Zeppa; D Hutson; N Einhorn
Journal:  Antimicrob Agents Chemother       Date:  1981-08       Impact factor: 5.191

3.  Chemoprophylaxis with cefoxitin and cephalothin in orthopedic surgery: a comparison.

Authors:  M B Rosenfeld; J Campos; K R Ratzan; I Uredo
Journal:  Antimicrob Agents Chemother       Date:  1981-05       Impact factor: 5.191

4.  Pharmacokinetics and clinical study of cefotetan in bile: prophylactic use in biliary tract surgery.

Authors:  P Cherrier; P Perrin; S Gueye; A M Bosio; P Tinel; P Blot; R Richer; F Fauvelle
Journal:  Pharm World Sci       Date:  1993-04-23

5.  Pharmacological study of cefazolin during intermittent and continuous infusion: a crossover investigation in humans.

Authors:  J P Thys; B Vanderkelen; J Klastersky
Journal:  Antimicrob Agents Chemother       Date:  1976-09       Impact factor: 5.191

6.  Biliary excretion of aztreonam in patients with biliary tract disease.

Authors:  O V Martinez; J U Levi; R G Devlin
Journal:  Antimicrob Agents Chemother       Date:  1984-03       Impact factor: 5.191

7.  Biliary levels of ceforanide.

Authors:  D E Kenady; M D Ram
Journal:  Antimicrob Agents Chemother       Date:  1983-05       Impact factor: 5.191

8.  Laboratory evaluation of FR10024 a new cephalosporin derivative.

Authors:  M Nishida; T Murakawa; T Kamimura; N Okada; S Fukada
Journal:  Antimicrob Agents Chemother       Date:  1977-01       Impact factor: 5.191

9.  Excretion of cefamandole, cefazolin, and cephalothin into T-tube bile.

Authors:  K R Ratzan; H B Baker; I Lauredo
Journal:  Antimicrob Agents Chemother       Date:  1978-06       Impact factor: 5.191

10.  Effects of cirrhosis on kinetics of aztreonam.

Authors:  C M MacLeod; E A Bartley; J A Payne; E Hudes; K Vernam; R G Devlin
Journal:  Antimicrob Agents Chemother       Date:  1984-10       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.